缝隙连接通道抑制：降低血压的新兴靶点？
Pannexin Channel Inhibition: An Evolving Target to Lower Blood Pressure?
机构信息
From the Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham.
出版信息
Circ Res. 2018 Feb 16;122(4):543-545. doi: 10.1161/CIRCRESAHA.118.312566.
Abstract
More than 50 years after spironolactone has come on the market its mechanism of action continues to expand. In this issue of , Good document the discovery that spironolactone is not only an inhibitor of the mineralocorticoid receptor, but also inhibits pannexin 1 channels.
摘要
螺内酯上市 50 多年后，其作用机制仍在不断扩展。在本期 中，Good 等人的研究报告指出，螺内酯不仅是一种盐皮质激素受体抑制剂，而且还能抑制 Pannexin 1 通道。
相似文献
1
Pannexin Channel Inhibition: An Evolving Target to Lower Blood Pressure?缝隙连接通道抑制：降低血压的新兴靶点？
Circ Res. 2018 Feb 16;122(4):543-545. doi: 10.1161/CIRCRESAHA.118.312566.
2
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.新型高效选择性非甾体盐皮质激素受体拮抗剂CS-3150的药理学特性
Eur J Pharmacol. 2015 Aug 15;761:226-34. doi: 10.1016/j.ejphar.2015.06.015. Epub 2015 Jun 11.
3
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.依普利酮：一种用于治疗高血压和心力衰竭的选择性醛固酮受体拮抗剂。
Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb.
4
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.难治性高血压的管理：聚焦于盐皮质激素受体拮抗剂
Vasc Health Risk Manag. 2017 Oct 16;13:403-411. doi: 10.2147/VHRM.S138599. eCollection 2017.
5
Aldosterone receptor antagonists: focus on eplerenone.醛固酮受体拮抗剂：聚焦依普利酮
Prog Cardiovasc Nurs. 2003 Winter;18(1):54-9. doi: 10.1111/j.0889-7204.2003.01936.x.
6
Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.高醛固酮血症期间的盐皮质激素和血管紧张素受体拮抗作用
Hypertension. 2002 Aug;40(2):124-9. doi: 10.1161/01.hyp.0000025904.23047.27.
7
Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?依普利酮对比螺内酯治疗抵抗性高血压：疗效和/或成本，还是仅仅是男性问题？
Curr Hypertens Rep. 2019 Mar 2;21(3):22. doi: 10.1007/s11906-019-0924-0.
8
Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.醛固酮合酶抑制剂作为抵抗性高血压的附加治疗的研究。
J Clin Hypertens (Greenwich). 2013 Mar;15(3):186-92. doi: 10.1111/jch.12051. Epub 2012 Dec 14.
9
Clinical implications of aldosterone blockade.醛固酮阻断的临床意义。
Am Heart J. 2002 Nov;144(5 Suppl):S12-8. doi: 10.1067/mhj.2002.129970.
10
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.螺内酯与依普利酮治疗特发性醛固酮增多症的比较。
Expert Opin Pharmacother. 2008 Mar;9(4):509-15. doi: 10.1517/14656566.9.4.509.
引用本文的文献
1
Pannexin1 channels-a potential therapeutic target in inflammation.泛连接蛋白1通道——炎症中的一个潜在治疗靶点。
Front Cell Dev Biol. 2022 Nov 9;10:1020826. doi: 10.3389/fcell.2022.1020826. eCollection 2022.
2
Endothelial pannexin-1 channels modulate macrophage and smooth muscle cell activation in abdominal aortic aneurysm formation.内皮细胞 Pannexin-1 通道调节腹主动脉瘤形成中的巨噬细胞和平滑肌细胞的激活。
Nat Commun. 2022 Mar 21;13(1):1521. doi: 10.1038/s41467-022-29233-4.
本文引用的文献
1
Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone.Pannexin 1 通道作为抗高血压药物螺内酯的一个意外新靶点。
Circ Res. 2018 Feb 16;122(4):606-615. doi: 10.1161/CIRCRESAHA.117.312380. Epub 2017 Dec 13.
2
Revisiting multimodal activation and channel properties of Pannexin 1.重新探讨 Pannexin 1 的多模态激活和通道特性。
J Gen Physiol. 2018 Jan 2;150(1):19-39. doi: 10.1085/jgp.201711888. Epub 2017 Dec 12.
3
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.螺内酯与安慰剂、比索洛尔及多沙唑嗪对比以确定难治性高血压的最佳治疗方案（PATHWAY-2）：一项随机、双盲、交叉试验
Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20.
4
Pannexin-1 channels do not regulate α1-adrenoceptor-mediated vasoconstriction in resistance arteries.泛连接蛋白-1通道不调节阻力动脉中α1-肾上腺素能受体介导的血管收缩。
Eur J Pharmacol. 2015 Mar 5;750:43-51. doi: 10.1016/j.ejphar.2015.01.024. Epub 2015 Jan 28.
5
The membrane protein Pannexin1 forms two open-channel conformations depending on the mode of activation.膜蛋白泛连接蛋白1根据激活模式形成两种开放通道构象。
Sci Signal. 2014 Jul 22;7(335):ra69. doi: 10.1126/scisignal.2005431.
6
Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors.平滑肌细胞盐皮质激素受体对血压的直接调节。
Nat Med. 2012 Sep;18(9):1429-33. doi: 10.1038/nm.2891.
7
Pannexin1 regulates α1-adrenergic receptor- mediated vasoconstriction.Pannexin1 调节 α1-肾上腺素能受体介导的血管收缩。
Circ Res. 2011 Jun 24;109(1):80-5. doi: 10.1161/CIRCRESAHA.110.237594. Epub 2011 May 5.
8
A new monoterpenoid glycoside from Myrica esculenta and the inhibition of angiotensin I-converting enzyme.一种来自毛杨梅的新型单萜糖苷及其对血管紧张素I转换酶的抑制作用。
Chem Pharm Bull (Tokyo). 2010 Oct;58(10):1408-10. doi: 10.1248/cpb.58.1408.
9
A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.一种新型的、强效且选择性的非甾体分子对盐皮质激素受体的拮抗作用模式。
J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.
10
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.难治性高血压：诊断、评估与治疗。美国心脏协会高血压研究理事会专业教育委员会的科学声明。
Hypertension. 2008 Jun;51(6):1403-19. doi: 10.1161/HYPERTENSIONAHA.108.189141. Epub 2008 Apr 7.
Zotero 插件